Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | EVP CLO & General Counsel | August 31, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IONIS PHARMACEUTICALS INC
Report date August 31, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,205 |
Reported balance
After 2026-08-31 transaction · row 1
1 source rowRow 1 · 2026-08-31 · Other · Acquired 63 · Balance 59,205 F1: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2021 Filed Jan 21, 2021 00:00 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Tax withholdingCommon Stock | 5,856 | $61.28 | $358,855.68 |
DisclosureSEC source: 0000874015-21-000033 · edgar.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,826 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 15, 2021 Filed Jan 21, 2021 00:00 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 16,504 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-21-000033 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 02:15 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 58,203 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-21-000013 · edgar.xml · derivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,203 Underlying: Common Stock · 58,203 shares Expires 2028-01-03 F1 · derivative.exercise_date: Grant on 01/04/2021 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/04/2021. 25% of the shares subject to the option will vest and become exercisable on 01/04/2022. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 23:10 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 169 | $44.46 | $7,512.90 |
DisclosureSEC source: 0000874015-20-000125 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,178 F1 · kind: Reporting 169 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2020. These 169 shares may not be sold until February 28, 2021 Read SEC document |
| February 29, 2020 Filed Mar 4, 2020 00:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 289 | $43.16 | $12,474.11 |
DisclosureSEC source: 0000874015-20-000056 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,009 F1 · kind: Reporting 289 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 29, 2020. These 289 shares may not be sold until August 30, 2020. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 22:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 3,882 | $59.60 | $231,367.20 |
DisclosureSEC source: 0000874015-20-000045 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,720 F1 · kind: The sale of shares owned was made pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/7/2020. F1 · shares: The sale of shares owned was made pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/7/2020. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.55 to $59.65, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:39 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 12,045 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000037 · edgar.xml · derivative · entry 4 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,552 Underlying: Common Stock · 12,045 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:39 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 24,205 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000037 · edgar.xml · derivative · entry 3 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,205 Underlying: Common Stock · 24,205 shares Expires not disclosed F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:39 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Tax withholdingCommon Stock | 4,277 | $62.06 | $265,430.62 |
DisclosureSEC source: 0000874015-20-000037 · edgar.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,602 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:39 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 12,045 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000037 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 02, 2020 Filed Jan 4, 2020 00:07 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (Right to Buy) · Derivative | 54,461 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-20-000016 · edgar.xml · derivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,461 Underlying: Common Stock · 54,461 shares Expires 2027-01-01 F1 · derivative.exercise_date: Grant on 01/02/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 00:56 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 161 | $45.70 | $7,358.42 |
DisclosureSEC source: 0000874015-19-000091 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,834 F1 · kind: Reporting 161shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2019. These 161 shares may not be sold until January 2, 2020. F1 · shares: Reporting 161shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2019. These 161 shares may not be sold until January 2, 2020. Read SEC document |
| April 05, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,252 | $0.00 Strike: $61.68 | $0.00 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · derivative · entry 24 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,969 Underlying: Common Stock · 2,252 shares Expires 2023-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,252 | $84.75 | $190,857.00 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 18 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,673 F5 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. F5 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. Read SEC document |
| April 05, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,252 | $61.68 | $138,903.36 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 17 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. F5 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $49.25 | $0.00 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · derivative · entry 23 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,638 Underlying: Common Stock · 8,000 shares Expires 2025-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,600 | $0.00 Strike: $47.34 | $0.00 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · derivative · entry 22 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,825 Underlying: Common Stock · 5,600 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,657 | $0.00 Strike: $61.57 | $0.00 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · derivative · entry 21 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,657 shares Expires 2022-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,365 | $0.00 Strike: $61.68 | $0.00 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · derivative · entry 20 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,221 Underlying: Common Stock · 20,365 shares Expires 2023-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,878 | $84.25 | $158,221.50 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 16 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,673 F8 · kind: The sale was made pursuant to shares owned. F8 · shares: The sale was made pursuant to shares owned. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,122 | $82.01 | $92,015.22 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 15 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,551 F8 · kind: The sale was made pursuant to shares owned. F8 · shares: The sale was made pursuant to shares owned. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.00 to $82.02, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (9) on this Form 4. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 8,000 | $84.29 | $674,320.00 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 14 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,673 F5 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. F5 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.20 to $84.35, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) on this Form 4. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 8,000 | $49.25 | $394,000.00 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 13 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. F5 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 3,600 | $82.10 | $295,560.00 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 12 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,673 F5 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. F5 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 3,600 | $47.34 | $170,424.00 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 11 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. F5 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,000 | $84.20 | $168,400.00 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 10 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,673 F5 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. F5 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,000 | $47.34 | $94,680.00 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 9 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. F5 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,657 | $82.03 | $217,953.71 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 8 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,673 F5 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. F5 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.00 to $82.05, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) on this Form 4. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,657 | $61.57 | $163,591.49 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 7 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. F5 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 4,873 | $82.19 | $400,511.87 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 6 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,673 F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plans adopted by the reporting person on 8/29/2018 and 3/5/2019. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plans adopted by the reporting person on 8/29/2018 and 3/5/2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.05 to $82.30, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 4,873 | $61.68 | $300,566.64 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 5 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plans adopted by the reporting person on 8/29/2018 and 3/5/2019. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plans adopted by the reporting person on 8/29/2018 and 3/5/2019. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 15,492 | $84.75 | $1,312,947.00 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 4 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,673 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 15,492 | $61.68 | $955,546.56 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 3 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,654 | $0.00 Strike: $61.68 | $0.00 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · derivative · entry 19 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,586 Underlying: Common Stock · 7,654 shares Expires 2023-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 7,654 | $84.83 | $649,288.82 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,673 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.75 to $85.025, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 23:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 7,654 | $61.68 | $472,098.72 |
DisclosureSEC source: 0000874015-19-000057 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 22:15 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 28,800 | $0.00 Strike: $61.57 | $0.00 |
DisclosureSEC source: 0000874015-19-000055 · edgar.xml · derivative · entry 3 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,657 Underlying: Common Stock · 28,800 shares Expires 2022-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 22:15 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 28,800 | $78.79 | $2,269,186.56 |
DisclosureSEC source: 0000874015-19-000055 · edgar.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,673 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.75 to $78.895, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 22:15 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 28,800 | $61.57 | $1,773,216.00 |
DisclosureSEC source: 0000874015-19-000055 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-19-000047 · edgar.xml · derivative · entry 8 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 18,800 | $0.00 Strike: $47.34 | $0.00 |
DisclosureSEC source: 0000874015-19-000047 · edgar.xml · derivative · entry 7 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,755 Underlying: Common Stock · 18,800 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 8,000 | $68.75 | $550,000.00 |
DisclosureSEC source: 0000874015-19-000047 · edgar.xml · nonDerivative · entry 6 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,673 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 8,000 | $39.87 | $318,960.00 |
DisclosureSEC source: 0000874015-19-000047 · edgar.xml · nonDerivative · entry 5 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 14,100 | $68.75 | $969,375.00 |
DisclosureSEC source: 0000874015-19-000047 · edgar.xml · nonDerivative · entry 4 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,673 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 14,100 | $47.34 | $667,494.00 |
DisclosureSEC source: 0000874015-19-000047 · edgar.xml · nonDerivative · entry 3 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 4,700 | $64.51 | $303,204.52 |
DisclosureSEC source: 0000874015-19-000047 · edgar.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,673 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.50 to $64.55, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 4,700 | $47.34 | $222,498.00 |
DisclosureSEC source: 0000874015-19-000047 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:01 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 275 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-19-000040 · edgar.xml · derivative · entry 3 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 275 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:01 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 275 | $59.50 | $16,362.50 |
DisclosureSEC source: 0000874015-19-000040 · edgar.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,673 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · price: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:01 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 275 | $39.87 | $10,964.25 |
DisclosureSEC source: 0000874015-19-000040 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.